Royalty Pharma (NASDAQ: RPRX) insider sale notice — 3,045 shares
Rhea-AI Filing Summary
Royalty Pharma plc filed a Form 144 reporting the proposed sale of 3,045 shares of Common Stock on 05/13/2026. The notice lists Merrill Lynch, 225 Liberty Street, Floor 37, New York as the broker and references the vesting of restricted stock unit awards granted under the issuer equity compensation plan.
Positive
- None.
Negative
- None.
Insights
Routine affiliate resale following RSU vesting; broker-listed sale of 3,045 shares.
The filing documents a proposed disposition of 3,045 shares of Common Stock dated 05/13/2026, tied to the vesting of restricted stock unit awards. The broker is listed as Merrill Lynch at 225 Liberty Street.
The notice is a regulatory disclosure of an intended sale method and quantity; timing and execution details beyond the listed date are not further detailed in the excerpt. Subsequent transaction reporting would show completion and actual proceeds.